GlassScriptPhysician profile
Kelsie M Coe
NPI 1336671734
$46,253.22
in general payments reported to CMS, 2019-2025
9 companies · $2,005 in 2025
The $2,005 reported for 2025 was more than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $1,160 · 2021: $30.58 · 2022: $42K · 2023: $1,223 · 2024: $133 · 2025: $2,005.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,547 · Food and Beverage: $813.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,547.49 |
| Food and Beverage | $813.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nuvasive, INC. | $41,408.70 | 2022 | |
| Medical Device Business Services, INC. | $1,222.61 | 2023 | |
| Arthrex, INC. | $1,105.90 | 2025 | |
| Peerless Surgical INC. | $1,014.99 | 2020 | |
| Novus Surgical Consultants | $955.57 | 2024-2025 | |
| Orthofix Medical, INC. | $293.31 | 2022 | |
| Acumed LLC | $144.66 | 2020 | |
| Orthopediatrics Corp. | $76.90 | 2025 | |
| Depuy Synthes Sales INC. | $30.58 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelsie Coe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.